FDA Approves FENOFIBRATE — Laurus Labs Limited

Laurus Labs Limited announced the approval of the ANDA for fenofibrate oral tablets, enabling it to compete in the U.S. cholesterol-lowering market following product label patent exclusivity. This regulatory milestone likely bolsters the manufacturer's commercial profile as it targets a segment driven by the incidence of dyslipidemia and cardiometabolic conditions.